Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
Biotechnology Fund
mutual fund
RYOAX
Payout Change
Suspended
Price as of:
$52.14
+0.6
+1.16%
primary theme
Health Care Sector Equity
share class
RYOAX (Mutual Fund)
Biotechnology Fund
Payout Change
Suspended
Price as of:
$52.14
+0.6
+1.16%
primary theme
Health Care Sector Equity
share class
RYOAX (Mutual Fund)
Biotechnology Fund
Payout Change
Suspended
Price as of:
$52.14
+0.6
+1.16%
primary theme
Health Care Sector Equity
share class
Name
As of 12/20/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-2.5%
1 yr return
1.8%
3 Yr Avg Return
-4.1%
5 Yr Avg Return
1.8%
Net Assets
$104 M
Holdings in Top 10
40.4%
52 WEEK LOW AND HIGH
$51.5
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 1.68%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 65.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$2,500
IRA
$1,000
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 12/20/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
RYOAX - Profile
Distributions
- YTD Total Return -2.5%
- 3 Yr Annualized Total Return -4.1%
- 5 Yr Annualized Total Return 1.8%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.82%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameBiotechnology Fund
-
Fund Family NameGuggenheim
-
Inception DateApr 14, 1998
-
Shares OutstandingN/A
-
Share ClassH
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerMichael Byrum
Fund Description
Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Biotechnology Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor.The Fund may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. Biotechnology Companies may be engaged in a variety of activities, including the research, development, and manufacture of various biotechnological products, services, and processes; manufacture and/or distribute biotechnological and biomedical products, including devices and instruments; provide or benefit significantly from scientific and technological advances in biotechnology; or provide processes or services instead of, or in addition to, products. Biotechnology Companies also may include companies that are significantly involved in multiple industries, including the biotechnology industry. The Fund also may purchase American Depositary Receipts (“ADRs”) to gain exposure to foreign Biotechnology Companies and U.S. government securities.Investments in derivative instruments, such as futures and options, have the economic effect of creating financial leverage in the Fund’s portfolio because such investments may give rise to losses that exceed the amount the Fund has invested in those instruments. Financial leverage will magnify, sometimes significantly, the Fund’s exposure to any increase or decrease in prices associated with a particular reference asset resulting in increased volatility in the value of the Fund’s portfolio. The value of the Fund’s portfolio is likely to experience greater volatility over short-term periods. While such financial leverage has the potential to produce greater gains, it also may result in greater losses, which in some cases may cause the Fund to liquidate other portfolio investments at a loss to comply with limits on leverage imposed by the Investment Company Act of 1940, satisfy margin or collateral requirements, or meet redemption requests.In an effort to ensure that the Fund is fully invested on a day-to-day basis, the Fund may conduct any necessary trading activity at or just prior to the close of the U.S. financial markets. As of June 30, 2024, the Fund has significant exposure to the Health Care Sector, as that sector is defined by the Global Industry Classification Standard, a widely recognized industry classification methodology developed by MSCI, Inc. and Standard & Poor’s Financial Services LLC. Also, as of June 30, 2024, the Fund’s investments are concentrated (i.e., more than 25% of its assets) in securities issued by companies in the Biotechnology Industry, a separate industry within the Health Care Sector.
Read More
RYOAX - Performance
Return Ranking - Trailing
| Period | RYOAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -2.5% | -30.1% | 21.2% | 87.42% |
| 1 Yr | 1.8% | -26.2% | 21.8% | 79.25% |
| 3 Yr | -4.1%* | -28.4% | 12.1% | 78.95% |
| 5 Yr | 1.8%* | -11.5% | 11.1% | 83.89% |
| 10 Yr | 3.1%* | -1.3% | 12.5% | 88.50% |
* Annualized
Return Ranking - Calendar
| Period | RYOAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 5.8% | -12.6% | 19.0% | 20.75% |
| 2022 | -14.6% | -53.9% | 3.2% | 73.68% |
| 2021 | -17.7% | -39.6% | 24.2% | 80.92% |
| 2020 | 12.2% | -13.6% | 178.2% | 57.05% |
| 2019 | 18.9% | 3.8% | 63.8% | 67.67% |
Total Return Ranking - Trailing
| Period | RYOAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -2.5% | -30.1% | 21.2% | 87.42% |
| 1 Yr | 1.8% | -26.2% | 21.8% | 79.25% |
| 3 Yr | -4.1%* | -28.4% | 12.1% | 78.95% |
| 5 Yr | 1.8%* | -11.5% | 11.1% | 83.89% |
| 10 Yr | 3.1%* | -1.3% | 12.5% | 88.50% |
* Annualized
Total Return Ranking - Calendar
| Period | RYOAX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 5.8% | -12.6% | 19.0% | 33.33% |
| 2022 | -13.3% | -53.9% | 3.7% | 72.37% |
| 2021 | 1.6% | -33.9% | 26.0% | 76.32% |
| 2020 | 21.8% | -0.7% | 180.6% | 53.69% |
| 2019 | 24.7% | 4.6% | 63.8% | 60.90% |
NAV & Total Return History
RYOAX - Holdings
Concentration Analysis
| RYOAX | Category Low | Category High | RYOAX % Rank | |
|---|---|---|---|---|
| Net Assets | 104 M | 6.43 M | 45.7 B | 77.36% |
| Number of Holdings | 70 | 25 | 430 | 59.12% |
| Net Assets in Top 10 | 44.9 M | 2.12 M | 23.9 B | 74.84% |
| Weighting of Top 10 | 40.42% | 18.4% | 78.1% | 79.25% |
Top 10 Holdings
- AbbVie, Inc. 8.74%
- Amgen, Inc. 6.01%
- Gilead Sciences, Inc. 4.67%
- Vertex Pharmaceuticals, Inc. 4.00%
- Regeneron Pharmaceuticals, Inc. 3.73%
- Corteva, Inc. 2.99%
- Alnylam Pharmaceuticals, Inc. 2.75%
- AstraZeneca plc 2.67%
- Biogen, Inc. 2.44%
- Moderna, Inc. 2.43%
Asset Allocation
| Weighting | Return Low | Return High | RYOAX % Rank | |
|---|---|---|---|---|
| Stocks | 99.52% | 89.92% | 106.13% | 19.50% |
| Cash | 2.01% | 0.00% | 33.01% | 50.94% |
| Other | 0.66% | -22.99% | 23.24% | 16.98% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 84.28% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 77.27% |
| Bonds | 0.00% | 0.00% | 12.39% | 81.76% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | RYOAX % Rank | |
|---|---|---|---|---|
| Healthcare | 96.38% | 59.26% | 100.00% | 93.51% |
| Basic Materials | 3.62% | 0.00% | 7.16% | 1.95% |
| Utilities | 0.00% | 0.00% | 0.00% | 77.27% |
| Technology | 0.00% | 0.00% | 22.69% | 78.57% |
| Real Estate | 0.00% | 0.00% | 5.89% | 79.22% |
| Industrials | 0.00% | 0.00% | 7.02% | 79.87% |
| Financial Services | 0.00% | 0.00% | 1.60% | 85.06% |
| Energy | 0.00% | 0.00% | 0.00% | 77.27% |
| Communication Services | 0.00% | 0.00% | 9.11% | 79.22% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 80.52% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 79.22% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | RYOAX % Rank | |
|---|---|---|---|---|
| US | 99.52% | 61.27% | 104.41% | 15.72% |
| Non US | 0.00% | 0.00% | 34.10% | 88.68% |
RYOAX - Expenses
Operational Fees
| RYOAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.68% | 0.08% | 4.48% | 26.42% |
| Management Fee | 0.85% | 0.03% | 1.25% | 79.87% |
| 12b-1 Fee | 0.25% | 0.00% | 1.00% | 51.95% |
| Administrative Fee | 0.25% | 0.03% | 0.25% | 91.89% |
Sales Fees
| RYOAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| RYOAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| RYOAX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 65.00% | 0.00% | 238.00% | 80.00% |
RYOAX - Distributions
Dividend Yield Analysis
| RYOAX | Category Low | Category High | RYOAX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 89.31% |
Dividend Distribution Analysis
| RYOAX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | SemiAnnual | Annual |
Net Income Ratio Analysis
| RYOAX | Category Low | Category High | RYOAX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.82% | -2.54% | 1.85% | 86.18% |
Capital Gain Distribution Analysis
| RYOAX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 12, 2024 | $1.702 | CapitalGainShortTerm |
| Dec 12, 2024 | $7.721 | CapitalGainLongTerm |
| Dec 20, 2022 | $0.899 | CapitalGainLongTerm |
| Dec 08, 2021 | $15.773 | OrdinaryDividend |
| Dec 09, 2020 | $6.950 | OrdinaryDividend |
| Dec 10, 2019 | $3.602 | CapitalGainLongTerm |
| Dec 11, 2018 | $3.331 | CapitalGainShortTerm |
| Dec 11, 2018 | $6.557 | CapitalGainLongTerm |
| Dec 12, 2017 | $0.088 | CapitalGainShortTerm |
| Dec 12, 2017 | $4.609 | CapitalGainLongTerm |
| Nov 17, 2015 | $1.276 | CapitalGainShortTerm |
| Nov 18, 2014 | $2.575 | CapitalGainShortTerm |
| Nov 18, 2014 | $0.585 | CapitalGainLongTerm |
RYOAX - Fund Manager Analysis
Managers
Michael Byrum
Start Date
Tenure
Tenure Rank
Apr 01, 1998
24.18
24.2%
Michael P. Byrum, CFA, Senior Vice President—Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies. He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. Prior to joining the Security Investors， Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. He earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst® designation and is a member of the CFA Institute and the CFA Society of Washington.
Ryan Harder
Start Date
Tenure
Tenure Rank
Mar 14, 2008
14.22
14.2%
Ryan A. Harder, CFA, Managing Director and Portfolio Manager of Security Investors. Mr. Harder joined the Investment Manager in 2010.He also joined Rydex Investments in 2004 as an assistant portfolio manager, was promoted to portfolio manager in 2005 and has served in his current capacity since 2008. Prior to joining Rydex Investments, he served in various capacities with WestLB Asset Management, including as an assistant portfolio manager, and worked in risk management at CIBC World Markets.He holds a B.A. in Economics from Brock University in Ontario, Canada and a Master of Science in International Securities, Investment and Banking from the ICMA Centre at the University of Reading in the U.K. Harder holds the Chartered Financial Analyst designation.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |
